Clinical, biochemical and morphological responses of patients with villous atrophy to oral betamethasone valerate and clobetasone butyrate.
10 patients with sub-total villous atrophy were given the topical corticosteroids betamethasone valerate or clobetasone butyrate for a period of 4 months whilst continuing on a normal diet. 5 patients improved symptomatically while red cell folate, urinary xylose and faecal fat excretion also improved. Brush border enzymes increased in patients treated with higher dosages of each drug. Enterocyte height increased and intra-epithelial lymphocytes were significantly decreased although overall morphological appearances remained indistinguishable from untreated coeliac disease. Suppression of the pituitary adrenal axis occurred in 8 patients and there did not appear to be useful separation of topical from systemic activity. These compounds offer no advantage over prednisolone in non-responsive coeliac disease.
D000284:Administration, Oral; D000287:Administration, Topical; D000305:Adrenal Cortex Hormones; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001623:Betamethasone / Q000031:analogs & derivatives*; D001624:Betamethasone Valerate / Q000008:administration & dosage / Q000627:therapeutic use*; D002446:Celiac Disease / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011239:Prednisolone
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; C010893:clobetasone butyrate; D001623:Betamethasone; D001624:Betamethasone Valerate; D011239:Prednisolone; D002990:Clobetasol